Overview of Experimental Vaccines and Antiviral Therapeutics for Henipavirus Infection.
Hendra
Henipavirus
Nipah
Therapeutics
Vaccine
Virus
Journal
Methods in molecular biology (Clifton, N.J.)
ISSN: 1940-6029
Titre abrégé: Methods Mol Biol
Pays: United States
ID NLM: 9214969
Informations de publication
Date de publication:
2023
2023
Historique:
medline:
24
8
2023
pubmed:
23
8
2023
entrez:
23
8
2023
Statut:
ppublish
Résumé
Hendra virus (HeV) and Nipah virus (NiV) are highly pathogenic paramyxoviruses, which have emerged in recent decades and cause sporadic outbreaks of respiratory and encephalitic disease in Australia and Southeast Asia, respectively. Over two billion people currently live in regions potentially at risk due to the wide range of the Pteropus fruit bat reservoir, yet there are no approved vaccines or therapeutics to protect against or treat henipavirus disease. In recent years, significant progress has been made toward developing various experimental vaccine platforms and therapeutics. Here, we describe these advances for both human and livestock vaccine candidates and discuss the numerous preclinical studies and the few that have progressed to human phase 1 clinical trial and the one approved veterinary vaccine.
Identifiants
pubmed: 37610570
doi: 10.1007/978-1-0716-3283-3_1
doi:
Substances chimiques
Antiviral Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-22Informations de copyright
© 2023. Springer Science+Business Media, LLC, part of Springer Nature.
Références
Mathieu C, Horvat B (2015) Henipavirus pathogenesis and antiviral approaches. Expert Rev Anti-Infect Ther 13(3):343–354. https://doi.org/10.1586/14787210.2015.1001838
doi: 10.1586/14787210.2015.1001838
pubmed: 25634624
Weatherman S, Feldmann H, de Wit E (2018) Transmission of henipaviruses. Curr Opin Virol 28:7–11. https://doi.org/10.1016/j.coviro.2017.09.004
doi: 10.1016/j.coviro.2017.09.004
pubmed: 29035743
Clayton BA, Wang LF, Marsh GA (2013) Henipaviruses: an updated review focusing on the pteropid reservoir and features of transmission. Zoonoses Public Health 60(1):69–83. https://doi.org/10.1111/j.1863-2378.2012.01501.x
doi: 10.1111/j.1863-2378.2012.01501.x
pubmed: 22709528
Halpin K, Young PL, Field HE, Mackenzie JS (2000) Isolation of Hendra virus from pteropid bats: a natural reservoir of Hendra virus. J Gen Virol 81(Pt 8):1927–1932
pubmed: 10900029
doi: 10.1099/0022-1317-81-8-1927
Field H, Schaaf K, Kung N, Simon C, Waltisbuhl D, Hobert H, Moore F, Middleton D, Crook A, Smith G, Daniels P, Glanville R, Lovell D (2010) Hendra virus outbreak with novel clinical features, Australia. Emerg Infect Dis 16(2):338–340. https://doi.org/10.3201/eid1602.090780
doi: 10.3201/eid1602.090780
pubmed: 20113576
pmcid: 2958006
Playford EG, McCall B, Smith G, Slinko V, Allen G, Smith I, Moore F, Taylor C, Kung YH, Field H (2010) Human Hendra virus encephalitis associated with equine outbreak, Australia, 2008. Emerg Infect Dis 16(2):219–223. https://doi.org/10.3201/eid1602.090552
doi: 10.3201/eid1602.090552
pubmed: 20113550
pmcid: 2957996
McCormack JG, Allworth AM, Selvey LA, Selleck PW (1999) Transmissibility from horses to humans of a novel paramyxovirus, equine morbillivirus (EMV). J Infect 38(1):22–23
pubmed: 10090501
doi: 10.1016/S0163-4453(99)90023-3
Selvey LA, Wells RM, McCormack JG, Ansford AJ, Murray K, Rogers RJ, Lavercombe PS, Selleck P, Sheridan JW (1995) Infection of humans and horses by a newly described morbillivirus. Med J Aust 162(12):642–645
pubmed: 7603375
doi: 10.5694/j.1326-5377.1995.tb126050.x
Westbury HA (2000) Hendra virus disease in horses. Rev Sci Tech 19(1):151–159
pubmed: 11189712
doi: 10.20506/rst.19.1.1203
Chua KB, Goh KJ, Wong KT, Kamarulzaman A, Tan PS, Ksiazek TG, Zaki SR, Paul G, Lam SK, Tan CT (1999) Fatal encephalitis due to Nipah virus among pig-farmers in Malaysia. Lancet 354(9186):1257–1259. https://doi.org/10.1016/S0140-6736(99)04299-3
doi: 10.1016/S0140-6736(99)04299-3
pubmed: 10520635
Chua KB, Bellini WJ, Rota PA, Harcourt BH, Tamin A, Lam SK, Ksiazek TG, Rollin PE, Zaki SR, Shieh W, Goldsmith CS, Gubler DJ, Roehrig JT, Eaton B, Gould AR, Olson J, Field H, Daniels P, Ling AE, Peters CJ, Anderson LJ, Mahy BW (2000) Nipah virus: a recently emergent deadly paramyxovirus. Science 288(5470):1432–1435
pubmed: 10827955
doi: 10.1126/science.288.5470.1432
Gurley ES, Montgomery JM, Hossain MJ, Bell M, Azad AK, Islam MR, Molla MA, Carroll DS, Ksiazek TG, Rota PA, Lowe L, Comer JA, Rollin P, Czub M, Grolla A, Feldmann H, Luby SP, Woodward JL, Breiman RF (2007) Person-to-person transmission of Nipah virus in a Bangladeshi community. Emerg Infect Dis 13(7):1031–1037. https://doi.org/10.3201/eid1307.061128
doi: 10.3201/eid1307.061128
pubmed: 18214175
pmcid: 2878219
Harcourt BH, Lowe L, Tamin A, Liu X, Bankamp B, Bowden N, Rollin PE, Comer JA, Ksiazek TG, Hossain MJ, Gurley ES, Breiman RF, Bellini WJ, Rota PA (2005) Genetic characterization of Nipah virus, Bangladesh, 2004. Emerg Infect Dis 11(10):1594–1597
pubmed: 16318702
pmcid: 3366751
doi: 10.3201/eid1110.050513
Homaira N, Rahman M, Hossain MJ, Epstein JH, Sultana R, Khan MS, Podder G, Nahar K, Ahmed B, Gurley ES, Daszak P, Lipkin WI, Rollin PE, Comer JA, Ksiazek TG, Luby SP (2010) Nipah virus outbreak with person-to-person transmission in a district of Bangladesh, 2007. Epidemiol Infect 138(11):1630–1636. https://doi.org/10.1017/S0950268810000695
doi: 10.1017/S0950268810000695
pubmed: 20380769
Hossain MJ, Gurley ES, Montgomery JM, Bell M, Carroll DS, Hsu VP, Formenty P, Croisier A, Bertherat E, Faiz MA, Azad AK, Islam R, Molla MA, Ksiazek TG, Rota PA, Comer JA, Rollin PE, Luby SP, Breiman RF (2008) Clinical presentation of Nipah virus infection in Bangladesh. Clin Infect Dis 46(7):977–984. https://doi.org/10.1086/529147
doi: 10.1086/529147
pubmed: 18444812
Hsu VP, Hossain MJ, Parashar UD, Ali MM, Ksiazek TG, Kuzmin I, Niezgoda M, Rupprecht C, Bresee J, Breiman RF (2004) Nipah virus encephalitis reemergence, Bangladesh. Emerg Infect Dis 10(12):2082–2087
pubmed: 15663842
pmcid: 3323384
doi: 10.3201/eid1012.040701
Luby SP, Rahman M, Hossain MJ, Blum LS, Husain MM, Gurley E, Khan R, Ahmed BN, Rahman S, Nahar N, Kenah E, Comer JA, Ksiazek TG (2006) Foodborne transmission of Nipah virus, Bangladesh. Emerg Infect Dis 12(12):1888–1894. https://doi.org/10.3201/eid1212.060732
doi: 10.3201/eid1212.060732
pubmed: 17326940
pmcid: 3291367
Quddus R, Alam S, Majumdar MA, Anwar S, Khan MR, Zahid Mahmud Khan AKS, Arif SM, Alam R, Siddique FM, Tan CT (2004) A report of 4 patients with Nipah encephalitis from Rajbari district, Bangladesh in the January 2004 outbreak. Neurol Asia 9:33–37
Rahman MA, Hossain MJ, Sultana S, Homaira N, Khan SU, Rahman M, Gurley ES, Rollin PE, Lo MK, Comer JA, Lowe L, Rota PA, Ksiazek TG, Kenah E, Sharker Y, Luby SP (2012) Date palm sap linked to Nipah virus outbreak in Bangladesh, 2008. Vector Borne Zoonotic Dis 12(1):65–72. https://doi.org/10.1089/vbz.2011.0656
doi: 10.1089/vbz.2011.0656
pubmed: 21923274
Arankalle VA, Bandyopadhyay BT, Ramdasi AY, Jadi R, Patil DR, Rahman M, Majumdar M, Banerjee PS, Hati AK, Goswami RP, Neogi DK, Mishra AC (2011) Genomic characterization of Nipah virus, West Bengal, India. Emerg Infect Dis 17(5):907–909. https://doi.org/10.3201/eid1705.100968
doi: 10.3201/eid1705.100968
pubmed: 21529409
pmcid: 3321761
Chadha MS, Comer JA, Lowe L, Rota PA, Rollin PE, Bellini WJ, Ksiazek TG, Mishra A (2006) Nipah virus-associated encephalitis outbreak, Siliguri, India. Emerg Infect Dis 12(2):235–240
pubmed: 16494748
pmcid: 3373078
doi: 10.3201/eid1202.051247
Chatterjee P (2018) Nipah virus outbreak in India. Lancet 391(10136):2200
pubmed: 31876482
doi: 10.1016/S0140-6736(18)31252-2
Ching PKG, de los Reyes VC, Sucaldito MN, Tayag E, Columna-Vingno AB, Malbas FF, Bolo GC, Sejvar JJ, Eagles D, Payford G, Dueger E, Kaku Y, Marikawa S, Kuroda M, Marsh GA, McCullough S, Foxwell AR (2015) Outbreak of Henipavirus infection, Philippines, 2014. Emerg Infect Dis 21:328
pubmed: 25626011
pmcid: 4313660
doi: 10.3201/eid2102.141433
Goh KJ, Tan CT, Chew NK, Tan PS, Kamarulzaman A, Sarji SA, Wong KT, Abdullah BJ, Chua KB, Lam SK (2000) Clinical features of Nipah virus encephalitis among pig farmers in Malaysia. N Engl J Med 342(17):1229–1235. https://doi.org/10.1056/NEJM200004273421701
doi: 10.1056/NEJM200004273421701
pubmed: 10781618
Islam MS, Sazzad HMS, Satter SM, Sultana S, Hossain MJ, Hasan M, Rahman M, Campbell S, Cannon DL, Ströher U (2016) Nipah virus transmission from bats to humans associated with drinking traditional liquor made from date palm sap, Bangladesh, 2011–2014. Emerg Infect Dis 22(4):664
pubmed: 26981928
pmcid: 4806957
doi: 10.3201/eid2204.151747
Chong HT, Hossain MJ, Tan CT (2008) Differences in epidemiologic and clinical features of Nipah virus encephalitis between the Malaysian and Bangladesh outbreaks. Neurology Asia 13:23–26
Mire CE, Satterfield BA, Geisbert JB, Agans KN, Borisevich V, Yan L, Chan Y-P, Cross RW, Fenton KA, Broder CC, Geisbert TW (2016) Pathogenic differences between Nipah virus Bangladesh and Malaysia strains in primates: implications for antibody therapy. Sci Rep 6:30916
pubmed: 27484128
pmcid: 4971471
doi: 10.1038/srep30916
Satterfield BA, Geisbert TW, Mire CE (2016) Inhibition of the host antiviral response by Nipah virus: current understanding and future perspectives. Futur Virol 11(5):331–344
doi: 10.2217/fvl-2016-0027
Satterfield BA, Dawes BE, Milligan GN (2016) Status of vaccine research and development of vaccines for Nipah virus. Vaccine 34(26):2971–2975. https://doi.org/10.1016/j.vaccine.2015.12.075
doi: 10.1016/j.vaccine.2015.12.075
pubmed: 26973068
Yoneda M, Georges-Courbot M-C, Ikeda F, Ishii M, Nagata N, Jacquot F, Raoul H, Sato H, Kai C (2013) Recombinant measles virus vaccine expressing the Nipah virus glycoprotein protects against lethal Nipah virus challenge. PLoS One 8(3):e58414
pubmed: 23516477
pmcid: 3597623
doi: 10.1371/journal.pone.0058414
Vigant F, Lee B (2011) Hendra and Nipah infection: pathology, models and potential therapies. Infect Disord Drug Targets 11(3):315–336. BSP/ID-DT/E-Pub/000178-11-3 [pii]
pubmed: 21488828
pmcid: 3253017
doi: 10.2174/187152611795768097
Prescott J, DeBuysscher BL, Feldmann F, Gardner DJ, Haddock E, Martellaro C, Scott D, Feldmann H (2015) Single-dose live-attenuated vesicular stomatitis virus-based vaccine protects African green monkeys from Nipah virus disease. Vaccine 33(24):2823–2829
pubmed: 25865472
pmcid: 4433813
doi: 10.1016/j.vaccine.2015.03.089
Ploquin A, Szecsi J, Mathieu C, Guillaume V, Barateau V, Ong KC, Wong KT, Cosset FL, Horvat B, Salvetti A (2013) Protection against henipavirus infection by use of recombinant adeno-associated virus-vector vaccines. J Infect Dis 207(3):469–478. https://doi.org/10.1093/infdis/jis699
doi: 10.1093/infdis/jis699
pubmed: 23175762
Pallister JA, Klein R, Arkinstall R, Haining J, Long F, White JR, Payne J, Feng YR, Wang LF, Broder CC, Middleton D (2013) Vaccination of ferrets with a recombinant G glycoprotein subunit vaccine provides protection against Nipah virus disease for over 12 months. Virol J 10:237. https://doi.org/10.1186/1743-422X-10-237
doi: 10.1186/1743-422X-10-237
pubmed: 23867060
pmcid: 3718761
Pallister J, Middleton D, Wang LF, Klein R, Haining J, Robinson R, Yamada M, White J, Payne J, Feng YR, Chan YP, Broder CC (2011) A recombinant Hendra virus G glycoprotein-based subunit vaccine protects ferrets from lethal Hendra virus challenge. Vaccine 29(34):5623–5630. https://doi.org/10.1016/j.vaccine.2011.06.015
doi: 10.1016/j.vaccine.2011.06.015
pubmed: 21689706
pmcid: 3153950
McEachern JA, Bingham J, Crameri G, Green DJ, Hancock TJ, Middleton D, Feng YR, Broder CC, Wang LF, Bossart KN (2008) A recombinant subunit vaccine formulation protects against lethal Nipah virus challenge in cats. Vaccine 26(31):3842–3852. https://doi.org/10.1016/j.vaccine.2008.05.016
doi: 10.1016/j.vaccine.2008.05.016
pubmed: 18556094
pmcid: 6186147
Meganck RM, Baric RS (2021) Developing therapeutic approaches for twenty-first-century emerging infectious viral diseases. Nat Med 27(3):401–410
pubmed: 33723456
doi: 10.1038/s41591-021-01282-0
Plotkin SA (2017) Vaccines for epidemic infections and the role of CEPI. Hum Vaccin Immunother 13(12):2755–2762. https://doi.org/10.1080/21645515.2017.1306615
doi: 10.1080/21645515.2017.1306615
pubmed: 28375764
pmcid: 5718831
Satterfield BA (2017) The future of preventing and treating Nipah virus infection, vol 3. Future Sci
Prasad AN, Woolsey C, Geisbert JB, Agans KN, Borisevich V, Deer DJ, Mire CE, Cross RW, Fenton KA, Broder CC (2020) Resistance of Cynomolgus monkeys to Nipah and Hendra virus disease is associated with cell-mediated and humoral immunity. J Infect Dis 221(Suppl 4):S436–S447
pubmed: 32022850
doi: 10.1093/infdis/jiz613
Mungall BA, Middleton D, Crameri G, Bingham J, Halpin K, Russell G, Green D, McEachern J, Pritchard LI, Eaton BT, Wang LF, Bossart KN, Broder CC (2006) Feline model of acute Nipah virus infection and protection with a soluble glycoprotein-based subunit vaccine. J Virol 80(24):12293–12302. https://doi.org/10.1128/JVI.01619-06
doi: 10.1128/JVI.01619-06
pubmed: 17005664
pmcid: 1676295
Middleton D, Pallister J, Klein R, Feng Y-R, Haining J, Arkinstall R, Frazer L, Huang J-A, Edwards N, Wareing M (2014) Hendra virus vaccine, a one health approach to protecting horse, human, and environmental health. Emerg Infect Dis 20(3):372
pubmed: 24572697
pmcid: 3944873
doi: 10.3201/eid2003.131159
Bossart KN, Rockx B, Feldmann F, Brining D, Scott D, LaCasse R, Geisbert JB, Feng YR, Chan YP, Hickey AC (2012) A Hendra virus G glycoprotein subunit vaccine protects African Green monkeys from Nipah virus challenge. Sci Transl Med 4(146):146ra107-146ra107
doi: 10.1126/scitranslmed.3004241
Mire CE, Geisbert JB, Agans KN, Feng YR, Fenton KA, Bossart KN, Yan L, Chan YP, Broder CC, Geisbert TW (2014) A recombinant Hendra virus G glycoprotein subunit vaccine protects nonhuman primates against Hendra virus challenge. J Virol 88(9):4624–4631. https://doi.org/10.1128/JVI.00005-14
doi: 10.1128/JVI.00005-14
pubmed: 24522928
pmcid: 3993805
Geisbert TW, Bobb K, Borisevich V, Geisbert JB, Agans KN, Cross RW, Prasad AN, Fenton KA, Yu H, Fouts TR (2021) A single dose investigational subunit vaccine for human use against Nipah virus and Hendra virus. NPJ Vaccines 6(1):1–12
doi: 10.1038/s41541-021-00284-w
Pickering BS, Hardham JM, Smith G, Weingartl ET, Dominowski PJ, Foss DL, Mwangi D, Broder CC, Roth JA, Weingartl HM (2016) Protection against henipaviruses in swine requires both, cell-mediated and humoral immune response. Vaccine 34(40):4777–4786. https://doi.org/10.1016/j.vaccine.2016.08.028
doi: 10.1016/j.vaccine.2016.08.028
pubmed: 27544586
pmcid: 6161494
DeBuysscher BL, Scott D, Marzi A, Prescott J, Feldmann H (2014) Single-dose live-attenuated Nipah virus vaccines confer complete protection by eliciting antibodies directed against surface glycoproteins. Vaccine 32(22):2637–2644
pubmed: 24631094
pmcid: 4829066
doi: 10.1016/j.vaccine.2014.02.087
Lo MK, Bird BH, Chattopadhyay A, Drew CP, Martin BE, Coleman JD, Rose JK, Nichol ST, Spiropoulou CF (2014) Single-dose replication-defective VSV-based Nipah virus vaccines provide protection from lethal challenge in Syrian hamsters. Antivir Res 101:26–29
pubmed: 24184127
doi: 10.1016/j.antiviral.2013.10.012
DeBuysscher BL, Scott D, Thomas T, Feldmann H, Prescott J (2016) Peri-exposure protection against Nipah virus disease using a single-dose recombinant vesicular stomatitis virus-based vaccine. NPJ Vaccines 1:16002
pubmed: 28706736
pmcid: 5505655
doi: 10.1038/npjvaccines.2016.2
Mire CE, Versteeg KM, Cross RW, Agans KN, Fenton KA, Whitt MA, Geisbert TW (2013) Single injection recombinant vesicular stomatitis virus vaccines protect ferrets against lethal Nipah virus disease. Virol J 10:353. https://doi.org/10.1186/1743-422X-10-353
doi: 10.1186/1743-422X-10-353
pubmed: 24330654
pmcid: 3878732
Mire CE, Geisbert JB, Agans KN, Versteeg KM, Deer DJ, Satterfield BA, Fenton KA, Geisbert TW (2019) Use of single-injection recombinant vesicular stomatitis virus vaccine to protect nonhuman primates against lethal Nipah virus disease. Emerg Infect Dis 25(6):1144–1152. https://doi.org/10.3201/eid2506.181620
doi: 10.3201/eid2506.181620
pubmed: 31107231
pmcid: 6537706
Kurup D, Wirblich C, Feldmann H, Marzi A, Schnell MJ (2015) Rhabdovirus-based vaccine platforms against henipaviruses. J Virol 89(1):144–154. https://doi.org/10.1128/JVI.02308-14
doi: 10.1128/JVI.02308-14
pubmed: 25320306
Shuai L, Ge J, Wen Z, Wang J, Wang X, Bu Z (2020) Immune responses in mice and pigs after oral vaccination with rabies virus vectored Nipah disease vaccines. Vet Microbiol 241:108549
pubmed: 31928698
doi: 10.1016/j.vetmic.2019.108549
Keshwara R, Shiels T, Postnikova E, Kurup D, Wirblich C, Johnson RF, Schnell MJ (2019) Rabies-based vaccine induces potent immune responses against Nipah virus. NPJ Vaccines 4:15. https://doi.org/10.1038/s41541-019-0109-5
doi: 10.1038/s41541-019-0109-5
pubmed: 31016033
pmcid: 6465360
Chattopadhyay A, Rose JK (2011) Complementing defective viruses that express separate paramyxovirus glycoproteins provide a new vaccine vector approach. J Virol 85(5):2004–2011
pubmed: 21177820
doi: 10.1128/JVI.01852-10
Kong D, Wen Z, Su H, Ge J, Chen W, Wang X, Wu C, Yang C, Chen H, Bu Z (2012) Newcastle disease virus-vectored Nipah encephalitis vaccines induce B and T cell responses in mice and long-lasting neutralizing antibodies in pigs. Virology 432(2):327–335
pubmed: 22726244
doi: 10.1016/j.virol.2012.06.001
Guillaume V, Contamin H, Loth P, Georges-Courbot MC, Lefeuvre A, Marianneau P, Chua KB, Lam SK, Buckland R, Deubel V (2004) Nipah virus: vaccination and passive protection studies in a hamster model. J Virol 78(2):834–840
pubmed: 14694115
pmcid: 368848
doi: 10.1128/JVI.78.2.834-840.2004
Weingartl HM, Berhane Y, Caswell JL, Loosmore S, Audonnet J-C, Roth JA, Czub M (2006) Recombinant Nipah virus vaccines protect pigs against challenge. J Virol 80(16):7929–7938
pubmed: 16873250
pmcid: 1563797
doi: 10.1128/JVI.00263-06
Guillaume-Vasselin V, Lemaitre L, Dhondt KP, Tedeschi L, Poulard A, Charreyre C, Horvat B (2016) Protection from Hendra virus infection with canarypox recombinant vaccine. NPJ Vaccines 1(1):1–8
doi: 10.1038/npjvaccines.2016.3
Kalodimou G, Veit S, Jany S, Kalinke U, Broder CC, Sutter G, Volz A (2020) A soluble version of Nipah virus glycoprotein G delivered by vaccinia virus MVA activates specific CD8 and CD4 T cells in mice. Viruses 12(1):26
doi: 10.3390/v12010026
Defang GN, Khetawat D, Broder CC, Quinnan GV (2010) Induction of neutralizing antibodies to Hendra and Nipah glycoproteins using a Venezuelan equine encephalitis virus in vivo expression system. Vaccine 29(2):212–220
pubmed: 21050901
pmcid: 3032421
doi: 10.1016/j.vaccine.2010.10.053
van Doremalen N, Lambe T, Sebastian S, Bushmaker T, Fischer R, Feldmann F, Haddock E, Letko M, Avanzato VA, Rissanen I, LaCasse R, Scott D, Bowden TA, Gilbert S, Munster V (2019) A single-dose ChAdOx1-vectored vaccine provides complete protection against Nipah Bangladesh and Malaysia in Syrian golden hamsters. PLoS Negl Trop Dis 13(6):e0007462. https://doi.org/10.1371/journal.pntd.0007462
doi: 10.1371/journal.pntd.0007462
pubmed: 31170144
pmcid: 6581282
Pedrera M, Macchi F, McLean RK, Franceschi V, Thakur N, Russo L, Medfai L, Todd S, Tchilian EZ, Audonnet J-C (2020) Bovine herpesvirus-4-vectored delivery of Nipah virus glycoproteins enhances T cell immunogenicity in pigs. Vaccine 8(1):115
doi: 10.3390/vaccines8010115
Lo MK, Spengler JR, Welch SR, Harmon JR, Coleman-McCray JD, Scholte FE, Shrivastava-Ranjan P, Montgomery JM, Nichol ST, Weissman D (2020) Evaluation of a single-dose nucleoside-modified messenger RNA vaccine encoding Hendra virus-soluble glycoprotein against lethal Nipah virus challenge in Syrian hamsters. J Infect Dis 221(Suppl 4):S493–S498
pubmed: 31751453
doi: 10.1093/infdis/jiz553
Nie J, Liu L, Wang Q, Chen R, Ning T, Liu Q, Huang W, Wang Y (2019) Nipah pseudovirus system enables evaluation of vaccines in vitro and in vivo using non-BSL-4 facilities. Emerg Microbes Infect 8(1):272–281. https://doi.org/10.1080/22221751.2019.1571871
doi: 10.1080/22221751.2019.1571871
pubmed: 30866781
pmcid: 6455126
Walpita P, Barr J, Sherman M, Basler CF, Wang L (2011) Vaccine potential of Nipah virus-like particles. PLoS One 6(4):e18437. https://doi.org/10.1371/journal.pone.0018437
doi: 10.1371/journal.pone.0018437
pubmed: 21494680
pmcid: 3071823
Walpita P, Cong Y, Jahrling PB, Rojas O, Postnikova E, Yu S, Johns L, Holbrook MR (2017) A VLP-based vaccine provides complete protection against Nipah virus challenge following multiple-dose or single-dose vaccination schedules in a hamster model. NPJ Vaccines 2:21. https://doi.org/10.1038/s41541-017-0023-7
doi: 10.1038/s41541-017-0023-7
pubmed: 29263876
pmcid: 5627259
Yoneda M, Guillaume V, Sato H, Fujita K, Georges-Courbot MC, Ikeda F, Omi M, Muto-Terao Y, Wild TF, Kai C (2010) The nonstructural proteins of Nipah virus play a key role in pathogenicity in experimentally infected animals. PLoS One 5(9):e12709. https://doi.org/10.1371/journal.pone.0012709
doi: 10.1371/journal.pone.0012709
pubmed: 20856799
pmcid: 2939873
Satterfield BA, Cross RW, Fenton KA, Borisevich V, Agans KN, Deer DJ, Graber J, Basler CF, Geisbert TW, Mire CE (2016) Nipah virus C and W proteins contribute to respiratory disease in ferrets. J Virol 90(14):6326–6343. https://doi.org/10.1128/JVI.00215-16
doi: 10.1128/JVI.00215-16
pubmed: 27147733
pmcid: 4936148
Satterfield BA, Borisevich V, Foster SL, Rodriguez SE, Cross RW, Fenton KA, Agans KN, Basler CF, Geisbert TW, Mire CE (2019) Antagonism of STAT1 by Nipah virus P gene products modulates disease course but not lethal outcome in the ferret model. Sci Rep 9(1):1–18
doi: 10.1038/s41598-019-53037-0
Satterfield BA, Cross RW, Fenton KA, Agans KN, Basler CF, Geisbert TW, Mire CE (2015) The immunomodulating V and W proteins of Nipah virus determine disease course. Nat Commun 6:7483
pubmed: 26105519
doi: 10.1038/ncomms8483
Huang Q, Zeng J, Yan J (2021) COVID-19 mRNA vaccines. J Genet Genomics 48:107
pubmed: 34006471
pmcid: 7959685
doi: 10.1016/j.jgg.2021.02.006
Broder CC, Weir DL, Reid PA (2016) Hendra virus and Nipah virus animal vaccines. Vaccine 34(30):3525–3534. https://doi.org/10.1016/j.vaccine.2016.03.075
doi: 10.1016/j.vaccine.2016.03.075
pubmed: 27154393
pmcid: 4933500
Broder CC, Xu K, Nikolov DB, Zhu Z, Dimitrov DS, Middleton D, Pallister J, Geisbert TW, Bossart KN, Wang LF (2013) A treatment for and vaccine against the deadly Hendra and Nipah viruses. Antivir Res 100(1):8–13. https://doi.org/10.1016/j.antiviral.2013.06.012
doi: 10.1016/j.antiviral.2013.06.012
pubmed: 23838047
McLean RK, Graham SP (2019) Vaccine development for Nipah virus infection in pigs. Front Vet Sci 6:16. https://doi.org/10.3389/fvets.2019.00016
doi: 10.3389/fvets.2019.00016
pubmed: 30778392
pmcid: 6369168
Chong HT, Kamarulzaman A, Tan CT, Goh KJ, Thayaparan T, Kunjapan SR, Chew NK, Chua KB, Lam SK (2001) Treatment of acute Nipah encephalitis with ribavirin. Annal Neurol 49(6):810–813
pubmed: 11409437
doi: 10.1002/ana.1062
Rockx B, Bossart KN, Feldmann F, Geisbert JB, Hickey AC, Brining D, Callison J, Safronetz D, Marzi A, Kercher L, Long D, Broder CC, Feldmann H, Geisbert TW (2010) A novel model of lethal Hendra virus infection in African green monkeys and the effectiveness of ribavirin treatment. J Virol 84(19):9831–9839. https://doi.org/10.1128/JVI.01163-10
doi: 10.1128/JVI.01163-10
pubmed: 20660198
pmcid: 2937751
Georges-Courbot MC, Contamin H, Faure C, Loth P, Baize S, Leyssen P, Neyts J, Deubel V (2006) Poly(I)-poly(C12U) but not ribavirin prevents death in a hamster model of Nipah virus infection. Antimicrob Agents Chemother 50(5):1768–1772. https://doi.org/10.1128/AAC.50.5.1768-1772.2006
doi: 10.1128/AAC.50.5.1768-1772.2006
pubmed: 16641448
pmcid: 1472238
Freiberg AN, Worthy MN, Lee B, Holbrook MR (2010) Combined chloroquine and ribavirin treatment does not prevent death in a hamster model of Nipah and Hendra virus infection. J Gen Virol 91(Pt 3):765–772. https://doi.org/10.1099/vir.0.017269-0
doi: 10.1099/vir.0.017269-0
pubmed: 19889926
pmcid: 2888097
Pallister J, Middleton D, Crameri G, Yamada M, Klein R, Hancock TJ, Foord A, Shiell B, Michalski W, Broder CC (2009) Chloroquine administration does not prevent Nipah virus infection and disease in ferrets. J Virol 83(22):11979–11982
pubmed: 19759137
pmcid: 2772715
doi: 10.1128/JVI.01847-09
Zhu Z, Bossart KN, Bishop KA, Crameri G, Dimitrov AS, McEachern JA, Feng Y, Middleton D, Wang LF, Broder CC, Dimitrov DS (2008) Exceptionally potent cross-reactive neutralization of Nipah and Hendra viruses by a human monoclonal antibody. J Infect Dis 197(6):846–853. https://doi.org/10.1086/528801
doi: 10.1086/528801
pubmed: 18271743
Mire CE, Satterfield BA, Geisbert JB, Agans KN, Borisevich V, Yan L, Chan YP, Cross RW, Fenton KA, Broder CC, Geisbert TW (2016) Pathogenic differences between Nipah virus Bangladesh and Malaysia strains in primates: implications for antibody therapy. Sci Rep 6:30916. https://doi.org/10.1038/srep30916
doi: 10.1038/srep30916
pubmed: 27484128
pmcid: 4971471
Geisbert TW, Mire CE, Geisbert JB, Chan YP, Agans KN, Feldmann F, Fenton KA, Zhu Z, Dimitrov DS, Scott DP, Bossart KN, Feldmann H, Broder CC (2014) Therapeutic treatment of Nipah virus infection in nonhuman primates with a neutralizing human monoclonal antibody. Sci Transl Med 6(242):242ra282. https://doi.org/10.1126/scitranslmed.3008929
doi: 10.1126/scitranslmed.3008929
Bossart KN, Geisbert TW, Feldmann H, Zhu Z, Feldmann F, Geisbert JB, Yan L, Feng YR, Brining D, Scott D, Wang Y, Dimitrov AS, Callison J, Chan YP, Hickey AC, Dimitrov DS, Broder CC, Rockx B (2011) A neutralizing human monoclonal antibody protects African green monkeys from Hendra virus challenge. Sci Transl Med 3 (105):105ra103:105ra103. https://doi.org/10.1126/scitranslmed.3002901
doi: 10.1126/scitranslmed.3002901
Bossart KN, Zhu Z, Middleton D, Klippel J, Crameri G, Bingham J, McEachern JA, Green D, Hancock TJ, Chan YP, Hickey AC, Dimitrov DS, Wang LF, Broder CC (2009) A neutralizing human monoclonal antibody protects against lethal disease in a new ferret model of acute Nipah virus infection. PLoS Pathog 5(10):e1000642. https://doi.org/10.1371/journal.ppat.1000642
doi: 10.1371/journal.ppat.1000642
pubmed: 19888339
pmcid: 2765826
Guillaume V, Contamin H, Loth P, Grosjean I, Courbot MCG, Deubel V, Buckland R, Wild TF (2006) Antibody prophylaxis and therapy against Nipah virus infection in hamsters. J Virol 80(4):1972–1978
pubmed: 16439553
pmcid: 1367164
doi: 10.1128/JVI.80.4.1972-1978.2006
Mire CE, Chan YP, Borisevich V, Cross RW, Yan L, Agans KN, Dang HV, Veesler D, Fenton KA, Geisbert TW, Broder CC (2019) A Cross-reactive humanized monoclonal antibody targeting fusion glycoprotein function protects ferrets against lethal Nipah virus and Hendra virus infection. J Infect Dis. https://doi.org/10.1093/infdis/jiz515
Mire CE, Chan Y-P, Borisevich V, Cross RW, Yan L, Agans KN, Dang HV, Veesler D, Fenton KA, Geisbert TW (2020) A cross-reactive humanized monoclonal antibody targeting fusion glycoprotein function protects ferrets against lethal Nipah virus and Hendra virus infection. J Infect Dis 221(Suppl 4):S471–S479
pubmed: 31686101
doi: 10.1093/infdis/jiz515
Broder CC (2013) Passive immunization and active vaccination against Hendra and Nipah viruses. Dev Biol 135:125–138
Playford EG, Munro T, Mahler SM, Elliott S, Gerometta M, Hoger KL, Jones ML, Griffin P, Lynch KD, Carroll H (2020) Safety, tolerability, pharmacokinetics, and immunogenicity of a human monoclonal antibody targeting the G glycoprotein of henipaviruses in healthy adults: a first-in-human, randomised, controlled, phase 1 study. Lancet Infect Dis 20(4):445–454
pubmed: 32027842
doi: 10.1016/S1473-3099(19)30634-6
Thakur N, Bailey D (2019) Advances in diagnostics, vaccines and therapeutics for Nipah virus. Microbes Infect. https://doi.org/10.1016/j.micinf.2019.02.002
Dawes BE, Kalveram B, Ikegami T, Juelich T, Smith JK, Zhang L, Park A, Lee B, Komeno T, Furuta Y, Freiberg AN (2018) Favipiravir (T-705) protects against Nipah virus infection in the hamster model. Sci Rep 8(1):7604. https://doi.org/10.1038/s41598-018-25780-3
doi: 10.1038/s41598-018-25780-3
pubmed: 29765101
pmcid: 5954062
Lo MK, Feldmann F, Gary JM, Jordan R, Bannister R, Cronin J, Patel NR, Klena JD, Nichol ST, Cihlar T, Zaki SR, Feldmann H, Spiropoulou CF, de Wit E (2019) Remdesivir (GS-5734) protects African green monkeys from Nipah virus challenge. Sci Transl Med 11(494). https://doi.org/10.1126/scitranslmed.aau9242
Steffen DL, Xu K, Nikolov DB, Broder CC (2012) Henipavirus mediated membrane fusion, virus entry and targeted therapeutics. Viruses 4(2):280–308. https://doi.org/10.3390/v4020280
doi: 10.3390/v4020280
pubmed: 22470837
pmcid: 3315217
Porotto M, Rockx B, Yokoyama CC, Talekar A, Devito I, Palermo LM, Liu J, Cortese R, Lu M, Feldmann H, Pessi A, Moscona A (2010) Inhibition of Nipah virus infection in vivo: targeting an early stage of paramyxovirus fusion activation during viral entry. PLoS Pathog 6(10):e1001168. https://doi.org/10.1371/journal.ppat.1001168
doi: 10.1371/journal.ppat.1001168
pubmed: 21060819
pmcid: 2965769
Uchida S, Horie R, Sato H, Kai C, Yoneda M (2018) Possible role of the Nipah virus V protein in the regulation of the interferon beta induction by interacting with UBX domain-containing protein 1. Sci Rep 8(1):7682. https://doi.org/10.1038/s41598-018-25815-9
doi: 10.1038/s41598-018-25815-9
pubmed: 29769705
pmcid: 5955904
Mire CE, Satterfield BA, Geisbert TW (2015) Pathogenesis of Hendra virus in humans. Human Emerging and Re-emerging Infections Set:207
Shaw ML, Garcia-Sastre A, Palese P, Basler CF (2004) Nipah virus V and W proteins have a common STAT1-binding domain yet inhibit STAT1 activation from the cytoplasmic and nuclear compartments, respectively. J Virol 78(11):5633–5641. https://doi.org/10.1128/JVI.78.11.5633-5641.2004
doi: 10.1128/JVI.78.11.5633-5641.2004
pubmed: 15140960
pmcid: 415790
Rodriguez JJ, Cruz CD, Horvath CM (2004) Identification of the nuclear export signal and STAT-binding domains of the Nipah virus V protein reveals mechanisms underlying interferon evasion. J Virol 78(10):5358–5367
pubmed: 15113915
pmcid: 400366
doi: 10.1128/JVI.78.10.5358-5367.2004
Rodriguez JJ, Horvath CM (2004) Host evasion by emerging paramyxoviruses: Hendra virus and Nipah virus v proteins inhibit interferon signaling. Viral Immunol 17(2):210–219. https://doi.org/10.1089/0882824041310568
doi: 10.1089/0882824041310568
pubmed: 15279700
Rodriguez JJ, Wang LF, Horvath CM (2003) Hendra virus V protein inhibits interferon signaling by preventing STAT1 and STAT2 nuclear accumulation. J Virol 77(21):11842–11845
pubmed: 14557668
pmcid: 229371
doi: 10.1128/JVI.77.21.11842-11845.2003
Rodriguez JJ, Parisien JP, Horvath CM (2002) Nipah virus V protein evades alpha and gamma interferons by preventing STAT1 and STAT2 activation and nuclear accumulation. J Virol 76(22):11476–11483
pubmed: 12388709
pmcid: 136769
doi: 10.1128/JVI.76.22.11476-11483.2002
Thompson KA, Strayer DR, Salvato PD, Thompson CE, Klimas N, Molavi A, Hamill AK, Zheng Z, Ventura D, Carter WA (1996) Results of a double-blind placebo-controlled study of the double-stranded RNA drug polyI:polyC12U in the treatment of HIV infection. Eur J Clin Microbiol Infect Dis 15(7):580–587
pubmed: 8874076
doi: 10.1007/BF01709367
Jiang Y, Chen D, Cai D, Yi Y, Jiang S (2021) Effectiveness of remdesivir for the treatment of hospitalized COVID-19 persons: a network meta-analysis. J Med Virol 93(2):1171–1174
pubmed: 32813283
doi: 10.1002/jmv.26443